ESMO Open
Health & Wellness Podcasts
ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research. The journal is published by BMJ on behalf of ESMO. http://esmoopen.bmj.com/ * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
Location:
United States
Genres:
Health & Wellness Podcasts
Description:
ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research. The journal is published by BMJ on behalf of ESMO. http://esmoopen.bmj.com/ * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
Twitter:
@ESMO_Open
Language:
English
Episodes
ESMO-Magnitude of Clinical Benefit Scale (V1.1) for early breast cancer therapies
7/20/2020
We evaluated the applicability of the scale and assessed the reasonableness of the generated scores in early breast cancer. Form 1 of the ESMO-MCBS v1.1 provided a generally robust tool for scoring of adjuvant breast cancer studies. Six shortcomings were identified including lack of information regarding acute and long-term toxicity, an inability to grade single arm de-escalation scales and limitations related to grading based on disease free survival (DFS). Read the paper on the ESMO Open...
Duration:00:14:58
ESMO-Magnitude of Clinical Benefit Scale of adjuvant colon cancer trials and meta-analyses
6/28/2020
Form 1 of the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) serves to grade therapies with curative intent. Form 1 provided very reasonable grading and expert field testers confirmed the reasonableness of generated scores. Exploratory toxicity evaluation and annotation was feasible but problematic given inconsistent toxicity reporting and limited results of late toxicity. Moreover, the experts identified the inability of crediting improved convenience...
Duration:00:07:34
Adjuvant and neoadjuvant therapies in melanoma
6/4/2020
The therapeutic landscape in melanoma is evolving rapidly. In this podcast, Jonathan Lim (a member of the ESMO Young Oncologists Committee) interviews Dr Teresa Amaral (the current chair of the ESMO Young Oncologists Committee and an expert in melanoma) for an update on the current practice and advances in adjuvant and neoadjuvant therapies in melanoma. Dr Amaral summarises key practice-changing studies which have established the current recommendations in this field, including CheckMate...
Duration:00:12:31
Emerging targets in cancer immunotherapy
4/5/2020
The advent of cancer immunotherapy has radically changed the field of oncology by improving the way many malignancies, including several aggressive and orphan diseases, are being treated with subsequent major improvement of patients’ prognosis. The first crucial and successful step in the field was the development of agents able to inactivate inhibitory immune receptors resulting in a subsequent increased anti-tumor response. Among them, antibodies blocking CTLA-4 (ipilimumab) and PD-1/PD-L1...
Duration:00:07:58
News in breast cancer 2019
4/5/2020
Anna Berghof talks to Matteo Lambertini - Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. The year 2019 has brought relevant new biological and clinical evidence to further improve the care of breast cancer patients. Regarding biological knowledge, in addition to the many important steps forward in enhancing the understanding of several aspects related to tumor biology and treatment resistance, more predictive...
Duration:00:13:34
Cancer care during the spread of Covid-19 in Italy: a young oncologist's perspective
3/25/2020
The Covid-19 pandemic is currently active all over Europe and especially in Italy. In this podcast Anna Berghof discusses with Matteo Lambertini - Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy - the difficulties of cancer treatment during this pandemic. Read the editorial: https://esmoopen.bmj.com/content/5/2/e000759
Duration:00:10:54
ESMO Presidential Symposium: ClarIDHy - ivosidenib in patients with advanced cholangiocarcinoma
2/12/2020
Advanced cholangiocarcinoma is associated with a particular impaired survival prognosis. So far targeted therapies with relevant clinical efficacy are missing. isocitrate dehydrogenase 1 (IDH1) mutations are observed in a fraction of patients with cholangiocarcinoma. The ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib ersus placebo in patients with advanced cholangiocarcinoma with an IDH1 mutation met its primary endpoint. Therefore, ivosidenib is a promising new...
Duration:00:07:00
News on the horizon in glioblastoma therapy
1/29/2020
Glioblastoma is the most frequent primary malignant brain tumor in adults. Methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) promotor is of prognostic as well as of predictive value, as patients with MGMT promotor methylation survive longer and have better responses to the alkylating chemotherapeutic agent temozolomid. The current first line therapy approaches after maximum safe resection include radio-chemotherapy with temozolomid, radio-chemotherapy with the combination of...
Duration:00:12:12
Highlights in Lung Cancer 2019
12/20/2019
There has been a lot of exciting trials in lung cancer reported in 2019. In this podcast, Jonathan Lim (YOC member) speaks to Professor Sanjay Popat about how these studies are practice-changing in the context of the current treatment landscape, and highlights what is on the horizon for 2020 (including targeting KRAS). Read the Abstract: https://esmoopen.bmj.com/content/5/1/e000676
Duration:00:26:42
Current biomarkers in immunotherapy
10/3/2019
Immunotherapy approaches have revolutionized medical oncology in the last years. However, still only a fraction of patients is responding. Given the risk of side effects without efficacy, therefore, biomarkers providing reliable and reproducible prediction of response are urgently needed. In this podcast, next generation biomarkers including the challenge of branched genomic evolution of cancer are discussed by Professor Samra Turajlic, The Royal Marsden Hospital, London, UK.
Duration:00:04:46
ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial
9/26/2019
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. The phase III trial Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA) showed a significant increase in progression free survival. In the now available finale survival analysis also the overall survival showed a statistical significant increase. Expert: Suresh S. Ramalingam, Winship Cancer Institute of Emory University,...
Duration:00:06:30
ESMO Presidential Symposium: Phase III PAOLA-1: Olaparib in newly diagnosed, advanced ovarian cancer
9/24/2019
The present podcast gives a short summary of the PAOLA-1 trial investigating the addition of Olaparib to bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. Expert: Isabelle L. Ray-Coquard Affiliation: Centre Leon Bèrard, Université Claude Bernard Lyon, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers de l'Ovaire (GINECO), Lyon, France
Duration:00:05:39
Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care
9/22/2019
In this podcast, Marina Parry, ESMO Open Digital Editor, speaks to Amanda Herbrand, Medical Oncologist Trainee working at University Hospital Basel, Switzerland, about her team’s work on off-label use (OLU) of Drug Treatments in Cancer Care, presented at ESMO Congress 2019 and a preprint of which is available on medRxiv: https://www.medrxiv.org/content/10.1101/19003152v1 With new drug treatments for cancer patients constantly being investigated in clinical trials, ensuring access to the ones...
Duration:00:18:19
The ESMO-Magnitude of Clinical Benefit Scale Group
9/9/2019
Despite all the efforts done so far, access to essential drugs in Oncology is still asymmetric. In this podcast, Teresa Amaral, member of the ESMO YOC, interviews Professor Martine Piccart (Scientific Director of the Institut Jules Bordet, Universite Libre de Bruxelles, Belgium) that shares valuable insights on the work that has been done on this field by the ESMO Magnitude of Clinical Benefit Scale (ESMO – MCBS) group. You can find more information about the ESMO-MCBS group in the following...
Duration:00:16:19
What is new on the horizon in Melanoma Brain Metastasis?
8/9/2019
Professor Kim Margolin (Department of Medical Oncology, City of Hope National Medical Center, Duarte, California) discusses in this podcast the different treatment strategies as well as the clinical challenge of handling melanoma patients with brain metastases. Brain metastases are a particular problem of melanoma patients, as this complication occurs early and frequently. Further, brain metastases are associated with a high symptom burden. Recently, systemic treatment approaches including...
Duration:00:07:00
ESMO 2018 Presidential Symposium – IMpassion130: Atezolizumab in triple negative breast cancer
10/4/2018
The IMpassion130 trial was a global, randomized, double-blind, Phase III study of Atezolizumab + nab-paclitaxel vs. placebo + nab-paclitaxel in treatment naïve locally advanced or metastatic triple negative breast cancer patients. Here, progression free survival was statistically significantly longer in patients treated with the combination of Atezolizumab + nab-paclitaxel compared to placebo + nab-paclitaxel. The side effect profile was favorable as no unexpected toxicities were observed in...
Duration:00:09:10
ESMO 2018 Presidential Symposium: radiotherapy to the primary tumor in metastatic prostate cancer
10/3/2018
Radiotherapy to the primary tumor has been a controversially discussed intervention in patients with newly diagnosed metastatic prostate cancer. Results of the STAMPEDE trial indicate that overall no survival advantage can be achieved by the addition of radiotherapy however subgroups might actually have a benefit. Here, patients with low volume, oligometastatic disease were shown to benefit in a predefined subgroup analysis. In this podcast, Dr. Parker provides insight on the practice...
Duration:00:06:24
The Metastatic Breast Cancer project: a novel patient-partnered initiative
9/5/2018
In this podcast, Marina Parry, ESMO Open Digital Editor, speaks to Elana Anastasio, Partnership Outreach Manager, and Brett Tomson, Scientific Outreach Manager, both from the Metastatic Breast Cancer (MBC) Project team at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, USA. The MBCproject is a novel model of a patient-partnered initiative whose aim is to accelerate the understanding of metastatic breast cancer by generating a massive open database of genomic information...
Duration:00:26:53
Biosimilars in oncology
7/24/2018
Biosimilars will soon become broadly available in the oncology field, raising important questions from both patients and healthcare providers. These questions need to be clarified upfront, in order to increase confidence in using these therapies. In this podcast, Teresa Amaral (YOC member) talks to Professor Josep Tabernero (ESMO President and Director of the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona about this timely topic – Biosimilars in Oncology. Read the full Abstract on...
Duration:00:09:49
Tumor evolution in non-small-cell lung cancer
7/20/2018
In this podcast, Marina Parry, ESMO Open Digital Editor, speaks to Nicholas McGranahan, Junior Group Leader of the Cancer Genome Evolution Group at University College London’s Cancer Institute about the role of bioinformatics in translating genomics research into the clinic and his most recent paper “Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution”, Cell, 2017 https://www.cell.com/cell/pdf/S0092-8674(17)31185-6.pdf. Read the full Abstract on the ESMO Open website.
Duration:00:13:42